Cellular Logistics careers

The Company has two products based on its patented biomaterial. EmVasc™ is a biomaterial delivered via intramuscular injection to diseased areas of the heart to facilitate repair of damaged tissue following myocardial infarction or heart failure. The Cellogicus™ biomaterial platform dramatically improves post-injection cell retention of regenerative medicine therapies.